Dawei Xuan
About Dawei Xuan
Dawei Xuan serves as the Vice President and Head of Clinical Pharmacology/DMPK at Erasca, Inc. in San Diego, California, bringing over two decades of experience in pharmaceutical research and development, including significant roles at Pfizer and Turning Point Therapeutics.
Work at Erasca
Dawei Xuan has been serving as Vice President, Head of Clinical Pharmacology/DMPK at Erasca, Inc. since 2021. In this role, he oversees clinical pharmacology and drug metabolism and pharmacokinetics (DMPK) efforts. His leadership contributes to the company's focus on advancing innovative cancer therapies. Based in San Diego, California, Xuan's work at Erasca builds on his extensive experience in the pharmaceutical industry.
Education and Expertise
Dawei Xuan holds a Ph.D. in Pharmaceutical Sciences from the University of Connecticut and a B.S. in Pharmaceutical Sciences from Peking University Health Science Center. His academic background provides a strong foundation for his expertise in quantitative modeling techniques, including pharmacokinetics (PK), pharmacokinetics/pharmacodynamics (PK/PD), and dose-exposure-response analysis. He has a proven track record in the strategic application of modeling and simulation in drug research and development.
Background
Xuan's career spans over three decades in the pharmaceutical industry, with significant roles at Pfizer and other organizations. He began his career at Hartford Hospital, where he worked for nine years in clinical pharmacokinetics and pharmacodynamics of antimicrobial agents. He later held various positions at Pfizer, culminating in his role as Senior Director of Clinical Pharmacology. He also served as Vice President of Clinical Pharmacology at Turning Point Therapeutics before joining Erasca.
Achievements
Throughout his career, Dawei Xuan has contributed to the discovery and development of three marketed medicines: Eliquis®, Inspra®, and Ibrance®. His extensive experience in developing antibody drug conjugates and his leadership in cross-functional project teams have been instrumental in advancing drug development initiatives. Xuan's proficiency in quantitative modeling has enhanced the understanding of drug behavior in clinical settings.
Previous Positions at Pfizer
Dawei Xuan had a long tenure at Pfizer, spanning 17 years, where he held multiple roles. He served as Manager of Clinical PK/PD, Associate Director of Clinical Pharmacology, Director of Clinical Pharmacology, and Senior Director of Clinical Pharmacology. His diverse roles involved overseeing clinical pharmacology efforts and contributing to various research and development projects within the organization.